Study-related adverse events. by Benjamin R. Lewis (22279166)

“…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”

Duration of blood pressure decrease. by Ai Wei (120010)

Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. by Xiang-Fan Chen (13932983)

Nitrate and nitrite treatment did not adversely affect multiple parameters of health but nitrate treatment significantly decreased movement following a startle. by Manuel García-Jaramillo (9930572)

Adverse health events. by Harika Dasari (18145735)

Subjects:

Ivermectin significantly decreases <i>L</i>. <i>loa</i> mf in BALB/c mice. by Rene Bilingwe Ayiseh (6900296)

The funnel plot based on COVID-19 infection in non-health care workers (A) and health care workers (B). by Zhuoyang Xia (21354186)

Subjects:

Subgroup Meta Analysis for HE Incidence Based on Treatment Duration and Dose. by Yangyang Hu (3309009)

Subjects:

A focus on the development of adverse events. by Fabrizio Schettini (12009517)

Subjects:

Adverse events. by Ayush Agarwal (12700069)

Significant compounds based on significant Analysis of Metabolites of <i>S. shimperi</i> extracts by METLIN on XCMS. by M. Azene (22553313)

“…<p>Significant compounds based on significant Analysis of Metabolites of <i>S. shimperi</i> extracts by METLIN on XCMS.…”

Sobel test for the significance of the mediation effect. by Getachew Magnar Kitila (19935139)

Adverse events and treatment interruptions. by Nicola Squillace (691608)

Adverse event summary. by Natalia Teleshova (553333)

Subjects:

S1 File - by Kassahun Fikadu (12575035)

Subjects:

Sample size estimation based on preliminary date. by Jacquelyn Y. Taylor (6386456)

Subjects:

Table1_Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.docx by Yanjing Zhang (401134)

“…</p>Methods<p>AE reports in the FDA Adverse Event Reporting System (FAERS) from 2019 Q4 (FDA approval of Lumateperone) to 2024 Q1 were collected and analyzed. …”

Table1_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Image1_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.JPEG by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Statistical significance results based on dominant hand measurements. by Mehmet Yetiş (10654227)